




# Angular Regioselective Synthesis of Varied Functionalized Hexahydro[1,2,4]triazolo[4,3-*a*]quinazolin-9-ones and Their Antiproliferative Action



## Table of Contents:



### Copies of NMR spectra of compounds 4 and 5:


(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-Ethyl 9-oxo-1-phenyl-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>4a</b>) .....</sup>	<b>S3</b>
(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-Ethyl 9-oxo-1-(<i>p</i>-tolyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>4b</b>) .....</sup>	<b>S6</b>
(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-Ethyl 9-oxo-1-(4-nitrophenyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>4c</b>) .....</sup>	<b>S9</b>
(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-Ethyl 9-oxo-1-(4-methoxyphenyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo-[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>4d</b>) .....</sup>	<b>S10</b>
(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-Ethyl 9-oxo-1-(4-chlorophenyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>4e</b>) .....</sup>	<b>S13</b>
(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-Ethyl 9-oxo-1-(3-(trifluoromethyl)phenyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo-[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>4f</b>) .....</sup>	<b>S14</b>
(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-3-Acetyl-1-(<i>p</i>-tolyl)-4a,5,8,9-tetrahydro[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-9(1<i>H</i>)-one (<b>4g</b>) ..</sup>	<b>S15</b>
(4a <i>S</i> <sup>*,8a<i>R</i><sup>*</sup>)-9-Oxo-<i>N</i>-Phenyl-1-(<i>p</i>-tolyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxamide (<b>4h</b>) .....</sup>	<b>S16</b>
(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-Ethyl 9-oxo-1-phenyl-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>5a</b>) .....</sup>	<b>S17</b>
(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-Ethyl 9-oxo-1-(<i>p</i>-tolyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>5b</b>) .....</sup>	<b>S21</b>
(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-Ethyl 1-(4-nitrophenyl)-9-oxo-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>5c</b>) .....</sup>	<b>S22</b>
(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-Ethyl 1-(4-methoxyphenyl)-9-oxo-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo-[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>5d</b>) .....</sup>	<b>S23</b>
(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-Ethyl 1-(4-chlorophenyl)-9-oxo-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>5e</b>) .....</sup>	<b>S24</b>
(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-Ethyl 9-oxo-1-(3-(trifluoromethyl)phenyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo-[4,3-<i>a</i>]quinazoline-3-carboxylate (<b>5f</b>) .....</sup>	<b>S25</b>

(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-3-Acetyl-1-(<i>p</i>-tolyl)-4a,5,8,9-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-9(1<i>H</i>)-one (<b>5g</b>) ...</sup>	<b>S26</b>
(4a <i>S</i> <sup>*,8a<i>S</i><sup>*</sup>)-9-Oxo-<i>N</i>-phenyl-1-(<i>p</i>-tolyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-3-carboxamide (<b>5h</b>) .....</sup>	<b>S27</b>
<b>Crystallographic details of compound 5a</b> .....	<b>S28</b>
<b>Copies of HRMS-ESI Spectra of compounds 4a-h and 5a-h</b> .....	<b>S29</b>




















**(4a*S*\*,8a*R*\*)-Ethyl 9-oxo-1-(*p*-tolyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**4b**)**





























(4a*S*<sup>\*</sup>,8a*R*<sup>\*</sup>)-Ethyl  
9-oxo-1-(4-chlorophenyl)-  
1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-*a*]quinazoline-  
3-carboxylate (**4e**)













(4aS\*,8aR\*)-3-Acetyl-1-(*p*-tolyl)-4a,5,8,9-tetrahydro[1,2,4]triazolo[4,3-*a*]quinazoline-9(1*H*)-one (**4g**)










(4aS\*,8aR\*)-9-Oxo-N-Phenyl-1-(p-tolyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-a]quinazoline-3-carboxamide (**4h**)























Parameter	Value
1 Data File Name	E:/ after/ Hungary work/ 19 20HASF/ 20HASF3AA-20 200204T13572 62-001/ 20HASF3AA/ 10/ pdta/ 1/ 1r
2 Title	20HASF3AA
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmrssu
6 Site	
7 Spectrometer	CAB AV4 500 MHZ BASIC
8 Author	
9 Solvent	CDCl <sub>3</sub>
10 Temperature	310.0
11 Pulse Sequence	zg30
12 Number of Scans	16
13 Receiver Gain	65
14 Relaxation Delay	1.0000
15 Pulse Width	10.8400
16 Acquisition Time	3.2768
17 Acquisition Date	2020-02-04T11:14:48
18 Modification	2020-02-04T05:59:16
19 Spectrometer Frequency	500.20
20 Spectral Width	10000.0
21 Lowest Frequency	-1922.6
22 Nucleus	1H
23 Acquired Size	32768
24 Spectral Size	65536




Parameter	Value
1 Data File Name	E:/ after/ Hungary work/ 19 20HASF/ 20HASF/ 20HASF3AA-20 200204T13572 62-001/ 20HASF3AA/ 11/ pdta/ 1/ 1r
2 Title	20HASF3AA
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmrssu
6 Site	
7 Spectrometer	CAB AV4 500 MHZ BASIC
8 Author	
9 Solvent	CDCl <sub>3</sub>
10 Temperature	310.0
11 Pulse Sequence	jmod
12 Number of Scans	256
13 Receiver Gain	101
14 Relaxation Delay	2.0000
15 Pulse Width	10.0000
16 Acquisition Time	1.0879
17 Acquisition Date	2020-02-04T11:29:31
18 Modification	2020-02-04T05:59:22
19 Spectrometer Frequency	125.78
20 Spectral Width	30120.5
21 Lowest Frequency	-2482.7
22 Nucleus	13C
23 Acquired Size	32768
24 Spectral Size	32768




(4a*S*\*,8a*S*\*)-Ethyl 1-(4-methoxyphenyl)-9-oxo-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**5d**)




Parameter	Value
1 Data File Name	E:/ after/Hungary/work/1920HASF/20HASF4/20HASF4A/2020204T135B12-001/20HASF4A/10/pdata/1/r/1r
2 Title	20HASF4A
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmrsu
6 Site	
7 Spectrometer	CAB AV4 500 MHZ BASIC
8 Author	
9 Solvent	$\text{CDCl}_3$
10 Temperature	310.0
11 Pulse Sequence	zg30
12 Number of Scans	16
13 Receiver Gain	85
14 Relaxation Delay	1.0000
15 Pulse Width	10.8400
16 Acquisition Time	3.2768
17 Acquisition Date	2020-02-04T11:34:46
18 Modification Date	2020-02-04T05:59:02
19 Spectrometer Frequency	500.20
20 Spectral Width	10000.0
21 Lowest Frequency	-1922.0
22 Nucleus	$^1\text{H}$
23 Acquired Size	32768
24 Spectral Size	65536







Parameter	Value
1 Data File Name	E:/ after/Hungary/work/1920HASF/20HASF/20HASF4A/2020204T135B12-001/20HASF4A/10/pdata/1/r/1r
2 Title	20HASF4A
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmrsu
6 Site	
7 Spectrometer	CAB AV4 500 MHZ BASIC
8 Author	
9 Solvent	$\text{CDCl}_3$
10 Temperature	310.0
11 Pulse Sequence	jmod
12 Number of Scans	256
13 Receiver Gain	101
14 Relaxation Delay	2.0000
15 Pulse Width	10.0000
16 Acquisition Time	1.0879
17 Acquisition Date	2020-02-04T11:48:55
18 Modification Date	2020-02-04T05:59:10
19 Spectrometer Frequency	125.78
20 Spectral Width	30120.5
21 Lowest Frequency	-2482.7
22 Nucleus	$^{13}\text{C}$
23 Acquired Size	32768
24 Spectral Size	32768




(4aS\*,8aS\*)-Ethyl 1-(4-chlorophenyl)-9-oxo-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-a]quinazoline-3-carboxylate (**5e**)









(4aS\*,8aS\*)-3-Acetyl-1-(*p*-tolyl)-4a,5,8,9-tetrahydro-[1,2,4]triazolo[4,3-*a*]quinazolin-9(1*H*)-one (5g)




Parameter	Value
1 Data File Name	E:/ after/ Hungary work/ 19 20HAS/ 20HASF/ F7/ 20HASF7AA-20 200207T13071 12-001/ 20HASF7AA/ 10/ pdata/ 1/ 1r
2 Title	20HASF7AA
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmsru
6 Site	
7 Spectrometer	CAB AV4 500 MHz BASIC
8 Author	
9 Solvent	$\text{CDCl}_3$
10 Temperature	310.0
11 Pulse Sequence	zg30
12 Number of Scans	16
13 Receiver Gain	65
14 Relaxation Delay	1.0000
15 Pulse Width	10.8400
16 Acquisition Time	3.2768
17 Acquisition Date	2020-02-07T11:33:08
18 Modification Date	2020-02-07T06:02:34
19 Spectrometer Frequency	500.20
20 Spectral Width	10000.0
21 Lowest Frequency	-1923.8
22 Nucleus	1H
23 Acquired Size	32768
24 Spectral Size	65536




Parameter	Value
1 Data File Name	E:/ after/ Hungary work/ 19 20HAS/ 20HASF/ F7/ 20HASF7AA-2 020207T1307 112-001/ 20HASF7AA/ 11/ pdata/ 1/ 1r
2 Title	20HASF7AA
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmsru
6 Site	
7 Spectrometer	CAB AV4 500 MHz BASIC
8 Author	
9 Solvent	$\text{CDCl}_3$
10 Temperature	310.0
11 Pulse Sequence	jmod
12 Number of Scans	256
13 Receiver Gain	101
14 Relaxation Delay	2.0000
15 Pulse Width	10.0000
16 Acquisition Time	1.0679
17 Acquisition Date	2020-02-07T11:47:35
18 Modification Date	2020-02-07T06:02:38
19 Spectrometer Frequency	125.78
20 Spectral Width	30120.5
21 Lowest Frequency	-2482.7
22 Nucleus	13C
23 Acquired Size	32768
24 Spectral Size	32768



(4aS\*,8aS\*)-9-Oxo-N-phenyl-1-(p-tolyl)-1,4a,5,8a,9-hexahydro-[1,2,4]triazolo[4,3-a]quinazoline-3-carboxamide (**5h**)



Parameter	Value
1 Data File Name	E:/ after/ Hungary work/ 19_20HASF/ 20HASF8/ 20HASF8B-20 200211T0809 012-001/ 20HASF8B/ 10/ pdta1/ 1/ 1r
2 Title	20HASF8B
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmsru
6 Site	
7 Spectrometer	CAB AV4 500 MHz BASIC
8 Author	
9 Solvent	CDCl <sub>3</sub>
10 Temperature	310.0
11 Pulse Sequence	zg30
12 Number of Scans	16
13 Receiver Gain	61
14 Relaxation Delay	1.0000
15 Pulse Width	10.8400
16 Acquisition Time	3.2768
17 Acquisition Date	2020-02-10T1
18 Modification Date	2:49:06 2020-02-11T0
19 Spectrometer Frequency	500.20
20 Spectral Width	10000.0
21 Lowest Frequency	-1925.1
22 Nucleus	1H
23 Acquired Size	32768
24 Spectral Size	65536




Parameter	Value
1 Data File Name	E:/ after/ Hungary work/ 19_20HASF/ 20HASF/ 20HASF8/ 20HASF8B-20 00211T080901 2-001/ 20HASF8B/ 11/ pdta1/ 1/ 1r
2 Title	20HASF8B
3 Comment	
4 Origin	Bruker BioSpin GmbH
5 Owner	nmsru
6 Site	
7 Spectrometer	CAB AV4 500 MHz BASIC
8 Author	
9 Solvent	CDCl <sub>3</sub>
10 Temperature	310.0
11 Pulse Sequence	jmod
12 Number of Scans	256
13 Receiver Gain	101
14 Relaxation Delay	2.0000
15 Pulse Width	10.0000
16 Acquisition Time	1.0879
17 Acquisition Date	2020-02-10T13 :03:31
18 Modification Date	2020-02-11T00 :06:56
19 Spectrometer Frequency	125.78
20 Spectral Width	30120.5
21 Lowest Frequency	-2482.7
22 Nucleus	13C
23 Acquired Size	32768
24 Spectral Size	32768

## Crystallographic details of compound 5a

**Table S1.** Crystal Data.

5a	
CCDC	
empirical formula	C <sub>18</sub> H <sub>18</sub> N <sub>4</sub> O <sub>3</sub>
fw	338.36
temp (K)	120(2)
$\lambda$ (Å)	1.54184
cryst syst	Triclinic
space group	P $\bar{1}$
<i>a</i> (Å)	9.5332(3)
<i>b</i> (Å)	10.4081(3)
<i>c</i> (Å)	16.8864(5)
$\alpha$ (deg)	89.227(2)
$\beta$ (deg)	81.130(2)
$\gamma$ (deg)	74.199(3)
<i>V</i> (Å <sup>3</sup> )	1592.20(9)
Z	4
$\rho_{\text{calc}}$ (Mg/m <sup>3</sup> )	1.412
$\mu(\text{Mo K}\alpha)$ (mm <sup>-1</sup> )	0.812
No. reflns.	42738
Unique reflns.	6682
Completeness to $\theta=67.684^\circ$	100%
GOOF ( $F^2$ )	1.029
R <sub>int</sub>	0.0503
R1 <sup>a</sup> ( $I \geq 2\sigma$ )	0.0377
wR2 <sup>b</sup> ( $I \geq 2\sigma$ )	0.0932

$$^a R1 = \frac{\sum |F_o| - |F_c|}{\sum |F_o|}, \quad ^b wR2 = \left\{ \frac{\sum [w(F_o^2 - F_c^2)^2]}{\sum [w(F_o^2)^2]} \right\}^{1/2}$$



(4aS\*,8aR\*)-Ethyl 9-oxo-1-phenyl-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-a]quinazoline-3-carboxylate (**4a**)

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

**4A**


PM-20230126-POS #76-89 RT: 0.39-0.45 AV: 14 NL: 5.62E9


T: FTMS + p ESI Full ms [125.0000-1000.0000]

339.14441

$\text{C}_{18}\text{H}_{19}\text{O}_3\text{N}_4 = 339.14517$

-2.24368 ppm





(4a*S*<sup>\*,8a*R*<sup>\*</sup>)-Ethyl 9-oxo-1-(*p*-tolyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**4b**)</sup>

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A


PM-20230126-POS #332-348 RT: 1.72-1.80 AV: 17 NL: 6.17E9


T: FTMS + p ESI Full ms [125.0000-1000.0000]

353.16007

$\text{C}_{19}\text{H}_{21}\text{O}_3\text{N}_4 = 353.16082$

-2.10694 ppm





(4a*S*\*,8a*R*\*)-Ethyl 9-oxo-1-(4-nitrophenyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**4c**)


D:\DATA\...\20230126\PM-20230126-POS


01/26/23 11:18:13

4A

PM-20230126-POS #529-549 RT: 2.73-2.83 AV: 21 NL: 1.70E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]

384.12941  
 $\text{C}_{18}\text{H}_{18}\text{O}_5\text{N}_5 = 384.13025$   
 -2.16161 ppm





(4a*S*<sup>\*</sup>,8a*R*<sup>\*</sup>)-Ethyl 9-oxo-1-(4-methoxyphenyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**4d**)

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13


4A


PM-20230126-POS #901-936 RT: 4.63-4.81 AV: 36 NL: 2.51E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]

373.10548

$\text{C}_{18}\text{H}_{18}\text{O}_3\text{N}_4\text{Cl} = 373.10619$

-1.90230 ppm





(4a*S*<sup>\*</sup>,8a*R*<sup>\*</sup>)-Ethyl 9-oxo-1-(4-chlorophenyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**4e**)


D:\DATA\...\20230126\PM-20230126-POS


01/26/23 11:18:13

4A

PM-20230126-POS #901-936 RT: 4.63-4.81 AV: 36 NL: 2.51E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]

373.10548  
 $\text{C}_{18}\text{H}_{18}\text{O}_3\text{N}_4\text{Cl} = 373.10619$   
 -1.90230 ppm





(4a*S*\*,8a*R*\*)-Ethyl 9-oxo-1-(3-(trifluoromethyl)phenyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**4f**)

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A


PM-20230126-POS #1060-1088 RT: 5.44-5.59 AV: 29 NL: 2.95E9


T: FTMS + p ESI Full ms [125.0000-1000.0000]

407.13179

$C_{19} H_{18} O_3 N_4 F_3 = 407.13255$

-1.85945 ppm





(4a*S*<sup>\*</sup>,8a*R*<sup>\*</sup>)-3-Acetyl-1-(*p*-tolyl)-4a,5,8,9-tetrahydro[1,2,4]triazolo[4,3-*a*]quinazoline-9(1*H*)-one (**4g**)

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A


PM-20230126-POS #1224-1244 RT: 6.28-6.38 AV: 21 NL: 3.22E9


T: FTMS + p ESI Full ms [125.0000-1000.0000]

323.14957

C<sub>18</sub>H<sub>19</sub>O<sub>2</sub>N<sub>4</sub> = 323.15025

-2.12153 ppm






(4a*S*<sup>\*</sup>,8a*R*<sup>\*</sup>)-9-Oxo-*N*-Phenyl-1-(*p*-tolyl)-1,4a,5,8,8a,9-hexahydro[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxamide (**4h**)


D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A

PM-20230126-POS #1365-1385 RT: 7.01-7.11 AV: 21 NL: 2.82E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]





(4a*S*<sup>\*</sup>,8a*S*<sup>\*</sup>)-Ethyl 9-oxo-1-phenyl-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-a]quinazoline-3-carboxylate (**5a**)

D:\DATA\...\20230126\PM-20230126-POS

01/26/23 11:18:13

4A


PM-20230126-POS #1512-1538 RT: 7.76-7.89 AV: 27 NL: 4.48E9


T: FTMS + p ESI Full ms [125.0000-1000.0000]

339.14446

C<sub>18</sub>H<sub>19</sub>O<sub>3</sub>N<sub>4</sub> = 339.14517

-2.08589 ppm





(4a*S*<sup>\*</sup>,8a*S*<sup>\*</sup>)-Ethyl 9-oxo-1-(*p*-tolyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**5b**)

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A


PM-20230126-POS #1696-1716 RT: 8.70-8.80 AV: 21 NL: 5.09E9


T: FTMS + p ESI Full ms [125.0000-1000.0000]

353.16005

C<sub>19</sub>H<sub>21</sub>O<sub>3</sub>N<sub>4</sub> = 353.16082

-2.18283 ppm





(4a*S*<sup>\*,8a*S*<sup>\*</sup>)-Ethyl 1-(4-nitrophenyl)-9-oxo-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**5c**)</sup>

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A


PM-20230126-POS #1830-1863 RT: 9.39-9.55 AV: 34 NL: 8.36E8


T: FTMS + p ESI Full ms [125.0000-1000.0000]

384.12980

$\text{C}_{18}\text{H}_{18}\text{O}_5\text{N}_5 = 384.13025$

-1.16572 ppm





(4aS\*,8aS\*)-Ethyl 1-(4-methoxyphenyl)-9-oxo-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-a]quinazoline-3-carboxylate (**5d**)


D:\DATA\..\20230126\PM-20230126-POS


01/26/23 11:18:13

4A

PM-20230126-POS #1973-2006 RT: 10.12-10.29 AV: 34 NL: 1.99E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]

369.15513  
 $\text{C}_{19}\text{H}_{21}\text{O}_4\text{N}_4 = 369.15573$   
-1.63223 ppm





(5a*S*<sup>\*,9a*S*<sup>\*</sup>)-Ethyl 3-(4-chlorophenyl)-5-oxo-3,5,5a,6,9,9a-hexahydro-[1,2,4]triazolo[4,3-*a*]quinazoline-1-carboxylate (**5e**)</sup>

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A


PM-20230126-POS #2129-2162 RT: 10.92-11.09 AV: 34 NL: 1.95E9


T: FTMS + p ESI Full ms [125.0000-1000.0000]

373.10560

C<sub>18</sub>H<sub>18</sub>O<sub>3</sub>N<sub>4</sub>Cl = 373.10619

-1.58870 ppm





(4a*S*<sup>\*,8a*S*<sup>\*</sup>)-Ethyl 9-oxo-1-(3-(trifluoromethyl)phenyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxylate (**5f**)</sup>

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13


4A


PM-20230126-POS #2291-2324 RT: 11.75-11.92 AV: 34 NL: 1.45E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]

407.13150

C<sub>19</sub>H<sub>18</sub>O<sub>3</sub>N<sub>4</sub>F<sub>3</sub> = 407.13255

-2.58945 ppm





(4aS\*,8aS\*)-3-Acetyl-1-(*p*-tolyl)-4a,5,8,9-tetrahydro-[1,2,4]triazolo[4,3-*a*]quinazolin-9(1*H*)-one (**5g**)


D:\DATA\..\20230126\PM-20230126-POS


01/26/23 11:18:13

4A

PM-20230126-POS #2438-2455 RT: 12.50-12.59 AV: 18 NL: 2.13E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]

323.14953  
C<sub>18</sub> H<sub>19</sub> O<sub>2</sub> N<sub>4</sub> = 323.15025  
-2.22286 ppm





(4a*S*<sup>\*,8a*S*<sup>\*</sup>)-9-Oxo-*N*-phenyl-1-(*p*-tolyl)-1,4a,5,8,8a,9-hexahydro-[1,2,4]triazolo[4,3-*a*]quinazoline-3-carboxamide (**5h**)</sup>

D:\DATA\..\20230126\PM-20230126-POS

01/26/23 11:18:13

4A

PM-20230126-POS #2580-2602 RT: 13.23-13.34 AV: 23 NL: 2.33E9  
T: FTMS + p ESI Full ms [125.0000-1000.0000]

